Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer's Disease: α7-nAChR Agonists in Human Clinical Trials

Current Pharmaceutical Design

Volumn 20, Issue 38, 2014, Pages 6014-6021

  Russo, Patrizia ^a   Bufalo, Alessandra Del ^a   Frustaci, Alessandra ^a   Fini, Massimo ^a   Cesario, Alfredo ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Alpha7 nAChR neurobiology; Alpha7 nAChR role in cognition; Alzheimer's disease; New drugs

Indexed keywords

ALPHA 7 ACETYLCHOLINE RECEPTOR; ALPHA 7 ACETYLCHOLINE RECEPTOR AGONIST; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; UNCLASSIFIED DRUG; BUNGAROTOXIN RECEPTOR; NICOTINIC AGENT;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; COGNITION; COGNITIVE DEFECT; DRUG TARGETING; HUMAN; MULTICENTER STUDY (TOPIC); NEUROBIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); AGONISTS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; TREATMENT OUTCOME; TRENDS;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NICOTINIC AGONISTS; TREATMENT OUTCOME;

EID: 84925875801     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140316130720     Document Type: Article

References (129)

1. World Health Organization and Alzheimer's Disease International. Dementia: a public health priority 2012. http://www. who. int/mental_health/publications/dementia_report_2 012/en/. Accessed July 28, 2013.
2. Obama administration presents national plan to fight Alzheimer's disease. http://www. hhs. gov/news/press/2012pres/05/20120515a. html Accessed July 28, 2013.
3. President Obama Proposes Increased Funding for Alzheimer's Research. http://www. usagainstalzheimers. org/press/usagainstalzheimersstatement-obamas-fy14-budget. Accessed July 28, 2013.
4. European Parliament resolution of 19 January 2011 on a European initiative on Alzheimer's disease and other dementias 2010/2084(INI) http://www. europarl. europa. eu/sides/getDoc. do?type=TA&languag e=EN&reference=P7-TA-2011-0016. Accessed July 28, 2013.
5. Wortmann M. Dementia: a global health priority-highlights from an ADI and World Health Organization report. Alzheimers Res Ther 2012; 4: 40.
6. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet 2012; 380: 1441-3.
7. Fuentes P. Clinical diagnosis in preclinical stage of Alzheimer's disease. Arch Med Res 2012; 43: 667-70.
8. Guzmán-Martínez L, Farías GA, Maccioni RB. Emerging noninvasive biomarkers for early detection of Alzheimer's disease. Arch Med Res 2012; 43: 663-6.
9. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 2010; 30: 2442-53.
10. Ni R, Marutle A, Nordberg A. Modulation of +7 nicotinic acetylcholine receptor and fibrillar amyloid-κ interactions in Alzheimer's disease brain. J Alzheimers Dis 2013; 33: 841-51.
11. Talantova M, Sanz-Blasco S, Zhang X, et al. A induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA 2013 Jun 17. [Epub ahead of print].
12. Oz M, Lorke DE, K-Heung S, Petroianu G. On the Interaction of κ-Amyloid Peptides and +7-Nicotinic Acetylcholine Receptors in Alzheimer's Disease. Curr Alzheimer Res 2013 Apr 29. [Epub ahead of print].
13. Hernandez CM, Dineley KT. +7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both? Curr Drug Targets 2012; 13: 613-22.
14. Parri HR, Hernandez CM, Dineley KT. Research update: Alpha7 nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 2011; 82: 931-42.
15. Guan ZZ, Zhang X, Ravid R, Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J Neurochem 2000; 74: 237-43.
16. Counts SE, He B, Che S, et al. Alpha7 nicotinic receptor upregulation in cholinergic basal forebrain neurons in Alzheimer disease. Arch Neurol 2007; 64: 1771-6.
17. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol 2005; 192: 215-25.
18. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982; 217: 408-14.
19. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 2000; 163: 495-529.
20. Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J Chem Neuroanat 2003; 26: 233-42.
21. Gauthier S, Reisberg B, Zaudig M, et al. International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet 2006; 367: 1262-70.
22. Haense C, Kalbe E, Herholz K, et al. Cholinergic system function and cognition in mild cognitive impairment. Neurobiol Aging 2012; 33: 867-77.
23. Herholz K. Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2008; 35 Suppl 1: S25-9.
24. Goekoop R, Scheltens P, Barkhoh F, Rombouts SARB. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation-a pharmacological fMRI study. Brain 2006; 129: 141-57.
25. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011; 221: 555-63.
26. Broussard GJ, Mytar J, Li RC, Klapstein GJ. The role of inflammatory processes in Alzheimer's disease. Inflammopharmacol 2012; 20: 109-26.
27. Rubio-Perez JM, Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientific World J 2012; 2012: 756357.
28. Holmes C. Review: systemic inflammation and Alzheimer's disease. Neuropathol Appl Neurobiol 2013; 39: 51-68.
29. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 2011; 8: 164-74.
30. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron 2009; 64: 28-32.
31. http://www. alzheimersepidemic. com/Drug2013. pdf. (Accessed July 28, 2013).
32. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
33. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012; 9: CD009132.
34. Masoodi N. ACP Journal Club. Review: cholinesterase inhibitors do not reduce progression to dementia from mild cognitive impairment. Ann Intern Med 2013; 158: JC3.
35. Rojas-Fernandez CH. Little evidence that cholinesterase inhibitors prevent progression of mild cognitive impairment to dementia, but they are associated with adverse effects. Evid Based Ment Health 2013; 16: 39.
36. Russo P, Frustaci A, Del Bufalo A, Fini M, Cesario A. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors. Curr Med Chem 2013; 20: 976-83.
37. Kawai H, Lazar R, Metherate R. Nicotinic control of axon excitability regulates thalamocortical transmission. Nat. Neurosci 2007; 10: 1168-75.
38. Zhang H, Sulzer D. Frequency-dependent modulation of dopamine release by nicotine. Nat. Neurosci 2004; 7: 581-2.
39. McKay BE, Placzek AN, Dani JA. Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem Pharmacol 2007; 74: 1120-33.
40. Heath CJ, Picciotto MR. Nicotine-induced plasticity during development: modulation of the cholinergic system and long-term consequences for circuits involved in attention and sensory processing. Neuropharmacol 2009; 56 Suppl 1: 254-62.
41. Bencherif M, Lippiello PM. Alpha7 neuronal nicotinic receptors: the missing link to understanding Alzheimer's etiopathology? Med Hypotheses 2010; 74: 281-5.
42. Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 2012; 287: 40207-15.
43. Corringer PJ, Poitevin F, Prevost MS, et al. Structure and pharmacology of pentameric receptor channels: from bacteria to brain. Structure 2012; 20: 941-56.
44. Uteshev VV. α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum. Adv Exp Med Biol 2012; 740: 603-38.
45. Shen JX, Yakel JL. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta Pharmacol Sin 2009 30: 673-80.
46. Cuevas J, Berg DK. Mammalian nicotinic receptors with alpha7 subunits that slowly desensitize and rapidly recover from alphabungarotoxin blockade. J Neurosci. 1998; 18: 10335-44.
47. Franklin JL, Johnson EM Jr. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci. 1992; 15: 501-8.
48. Couturier S, Bertrand D, Matter JM, et al. A neuronal nicotinic acetylcholinereceptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 1990; 5: 847-56.
49. Russo P, Taly A. α7-Nicotinic acetylcholine receptors: an old actor for new different roles. Curr Drug Targets 2012; 13: 574-8.
50. Uteshev VV, Meyer EM, Papke RL. Activation and inhibition of native neuronal alphabungarotoxin-sensitive nicotinic ACh receptors. Brain Research 2002; 948: 33-46.
51. Monod J, Wyman J, Changeux JP. On the nature of allosteric transitions: A plausible model. J Mol Biol. 1965; 12: 88-118.
52. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 2009; 8: 733-50.
53. Changeux JP. Allostery and the Monod-Wyman-Changeux model after 50 years. Annu Rev Biophys 2012; 41: 103-33.
54. Changeux JP. The concept of allosteric interaction and its consequences for the chemistry of the brain. J Biol Chem 2013; Jul 22. [Epub ahead of print].
55. Edelstein SJ, Le Novère N. Cooperativity of allosteric receptors. J Mol Biol 2013; 425: 1424-32.
56. Liu Q, Huang Y, Xue F, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 2009; 29: 918-29.
57. Liu Q, Huang Y, Shen J, Steffensen S, Wu J. Functional α7β2 nicotinic acetylcholine receptors expressed in hippocampal interneurons exhibit high sensitivity to pathological level of amyloid peptides. BMC Neurosci 2012; 13: 155.
58. Wallace TL, Bertrand D. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochem Pharmacol 2013; 85: 1713-20.
59. Guillem K, Bloem B, Poorthuis RB, et al. Nicotinic acetylcholine receptor r2 subunits in the medial prefrontal cortex control attention. Science 2011; 333: 888-91.
60. Carson R, Craig D, McGuinness B, et al. Alpha7 nicotinic acetylcholine receptor gene and reduced risk of Alzheimer's disease. J Med Genet 2008; 45: 244-8.
61. Chini B, Raimond E, Elgoyhen AB, et al. Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics. 1994; 19: 379-81.
62. Riley B, Williamson M, Collier D, Wilkie H, Makoff A. A 3-Mb map of a large Segmental duplication overlapping the alpha7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14. Genomics 2002; 79: 197-209.
63. Flomen RH, Davies AF, Di Forti M, et al. The copy number variant involving part of the alpha 7 nicotinic receptor gene contains a polymorphic inversion. Eur J Hum Gen 2008; 16: 1364-71.
64. Raux G, Bonnet-Brilhault F, Louchart S, et al. The-2 bp deletion in exon 6 of the 'alpha 7-like' nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Mol Psych 2002; 7: 1006-11.
65. Araud T, Graw S, Berger R, et al. The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function. Biochem Pharmacol 2011; 82: 904-14.
66. Fehér A, Juhász A, Rimanóczy A, et al. Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia. Dement Geriatr Cogn Disord 2009; 28: 56-62.
67. Neri M, Bonassi S, Russo P. Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia. Curr Drug Targets 2012; 13: 636-43.
68. Hurst R, Rollema H, Bertrand D. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol Ther 2013; 137: 22-54.
69. Perrier AL, Massoulie J, Krejci E. PRiMA: the membrane anchor of acetylcholinesterase in the brain. Neuron 2002; 33: 275-85.
70. Matta SG, Balfour DJ, Benowitz NL, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacol. (Berl) 2007; 190: 269-319.
71. Gyermek L. New local anesthetic agents. Anesthesiology. 1996; 85: 226-227.
72. Wathey JC, Nass MN, Lester H. A. Numerical reconstruction of the quantal event at nicotinic synapses. Biophys. J. 1979; 27: 145-64.
73. Bartol TM, Land BR, Salpeter EE, Salpeter MM. Monte-Carlo simulation of miniature end-plate current generation in the vertebrate neuromuscular junction. Biophys J. 1991; 59: 1290-1307.
74. Buccafusco JJ, Beach JW, Terry AV Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 2009, 328: 364-70.
75. Russo P, Nastrucci C, Alzetta G, Szalai C. Tobacco habit: historical, cultural, neurobiological, and genetic features of people's relationship with an addictive drug. Perspect Biol Med 2011; 54: 557-77.
76. Cardinale A, Nastrucci C, Cesario A, Russo P. Nicotine: specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol 2012; 42: 68-89.
77. Elrod K, Buccafusco JJ, Jackson WJ. Nicotine enhances delayed matching-to sample performance by primates. Life Sci 1988; 43: 277-87.
78. Buccafusco JJ, Jackson WJ. Beneficial effects of nicotine administered prior to a delayed matching-to-sample task in young and aged monkeys. Neurobiol Aging. 1991; 12: 233-8.
79. Newhouse P, Kellar K, Aisen P, et al. Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. Neurology 2012; 78: 91-101.
80. http://www. alz. org/national/documents/topicsheet_mci. pdf. (Accessed July 28, 2013).
81. Benowitz NL, Hukkanen J, Jacob P 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009; 192: 29-60.
82. Bowman ER, Mc KH Jr. Studies on the metabolism of (-)-cotinine in the human. J. Pharmacol. Exp. Ther. 1962; 135: 306-11.
83. Benowitz NL, Kuyt F, Jacob P III, Jones R T, Osman A. Cotinine disposition and effects. Clin. Pharmacol. Ther. 1983; 34: 604-11.
84. Moran VE. Cotinine: Beyond that Expected, More than a Biomarker of Tobacco Consumption. Front Pharmacol 2012; 3: 173.
85. Taly A, Charon S. α7 nicotinic acetylcholine receptors: a therapeutic target in the structure era. Curr Drug Targets 2012; 13: 695-706.
86. Thomsen MS, Mikkelsen JD. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Curr Drug Targets 2012, 13: 707-20.
87. Toyohara J, Hashimoto K. alpha7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease. The Open Med Chem Journ 2010; 4: 37-56.
88. Cannon CE, Puri V, Vivian JA, et al. The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys. Neuropharmacol 2013; 64: 191-6.
89. Briggs CA, Anderson DJ, Brioni JD, et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21. In vitro and in vivo. Pharmacol Biochem Behav. 1997; 57: 231-41.
90. Kitagawa H, Takenouchi T, Azuma R, et al. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacol 2003; 28: 542-51.
91. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-8.
92. http://www. clinicaltrials. gov/ct2/show/NCT00414622. (Accessed July 28, 2013).
93. Malysz J, Anderson DJ, Gronlien JH, Ji J, et al. In vitro pharmacological characterization of a novel selective alpha 7 neuronal nicotinic acetylcholine receptor agonist ABT-107. 39th Annual Meeting of Society for Neuroscience (SFN); October 17-21, 2009; Chicago, Ill.
94. Othman AA, Lenz RA, Zhang J, et al. Single-and multiple-dose pharmacokinetics, safety and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers J Clin Pharmacol 2011; 51: 512-26.
95. http://clinicaltrials. gov/ct2/results?term=NCT01549834. (Accessed July 28, 2013).
96. Prickaerts J, van Goethem NP, Chesworth R, et al. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacol 2012; 62: 1099-110.
97. http://www. envivopharma. com/pdf/EVP-6124AAICPressConf. pdf. (Accessed July 28, 2013).
98. http://www. envivopharma. com/news-item. php?id=45. (Accessed July 28, 2013).
99. Wallace TL, Callahan PM, Tehim A, et al. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 2011; 336: 242-53.
100. http://clinicaltrials. gov/ct2/results?term=NCT00582855. (Accessed July 28, 2013).
101. http://www. drugs. com/clinical_trials/memory-pharmaceuticalsannounces-positive-phase-2a-results-mem-3454-alzheimer-s-2538. html. (Accessed July 28, 2013).
102. http://sigma. larvol. com/merge/sigma/trialzilla_product. php? e1=306&sourcepg=TZP. (Accessed July 28, 2013).
103. http://www. clinicaltrials. gov/ct2/results?term=AQW051& Search=Search. (Accessed July 28, 2013).
104. http://clinicaltrials. gov/ct2/results?term=NCT00582855. (Accessed July 28, 2013).
105. Mazurov AA, Kombo DC, Hauser TA, et al. Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2. 2. 2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders. J Med Chem 2012; 55: 9793-809.
106. http://clinicaltrials. gov/ct2/results?term=NCT01254448 (Accessed July 28, 2013).
107. Takada-Takatori Y, Kume T, Sugimoto M, et al. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacol 2006; 51: 474-86.
108. Takada-Takatori Y, Kume T, Ohgi Y, et al. Mechanisms of alpha7-nicotinic receptor up-regulation and sensitization to Donepezil induced by chronic Donepezil treatment. Eur J Pharmacol 2008; 590: 150-6.
109. Tyagi E, Agrawal R, Nath C, Shukla R. Cholinergic protection via alpha7 nicotinic acetylcholine receptors and PI3K-Akt pathway in LPS-induced neuroinflammation. Neurochem Int 2010; 56: 135-42.
110. Kamat PK, Tota S, Rai S, et al. Okadaic acid induced neurotoxicity leads to central cholinergic dysfunction in rats. Eur J Pharmacol 2012; 690: 90-8.
111. Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacol. 1999; 38: 1253-59.
112. Maskell PD, Speder P, Newberry NR, Bermudez I. Inhibition of human h7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. Br J Pharmacol 2003; 140: 1313-19.
113. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine in man. Neurosci Lett. 1995; 195: 137-39.
114. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18: S23-32.
115. Becker B, Klein EM, Striepens N, et al. Nicotinic acetylcholine receptors contribute to learning-induced metaplasticity in the hippocampus. J Cogn Neurosci 2013; 25: 986-97.
116. Niedowicz DM, Beckett TL, Matveev S, et al. Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol 2012; 72: 564-70.
117. Gill JK, Savolainen M, Young GT, et al. Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA 2011; 108: 5867-72.
118. Gill JK, Dhankher P, Sheppard TD, Sher E, Millar NS. A series of [7 nicotinic acetylcholine receptor allosteric modulators with close chemical similarity but diverse pharmacological properties. Mol Pharmacol 2012; 81: 710-18.
119. Storch A, Schrattenholz A, Cooper JC, et al. 1995. Physosotigmine, galantamine and codeine act as noncompetitive nicotinic receptor agonists on clonal rat pheochromocytoma cells. Eur J Pharmacol. 1995; 290: 207-19.
120. Samochocki M, Höffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003, 305: 1024-36.
121. Loveman E, Green C, Kirby J, et al. The clinical and costeffectiveness of Donepezil, rivastigmine, galantamine and Memantine for Alzheimer's disease. Health Technol Assess 2006; 10: 1-160.
122. Bond M, Rogers G, Peters J, et al. The effectiveness and costeffectiveness of Donepezil, galantamine, rivastigmine and Memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess 2012; 16: 1-470.
123. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006; 1: CD001747.
124. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand Suppl 2000; 176: 68-73.
125. Ludwig J, Höffle-Maas A, Samochocki M, et al. Localization by site-directed mutagenesis of a galantamine binding site on α7 nicotinic acetylcholine receptor extracellular domain. J Recept Signal Transduct Res 2010; 30: 469-83.
126. Cubells JF, Deoreo EH, Harvey PD, et al. Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13. 3 deletion syndrome. Am J Med Genet A 2011; 155A: 805-10.
127. Ben-Shachar S, Lanpher B, German JR, et al. Microdeletion 15q13. 3: A locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet 2009; 46: 382-8.
128. Deutsch SI, Schwartz BL, Schooler NR, et al. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: A novel agonist strategy. Schizophr Res 2013 Jun 12. [Epub ahead of print].
129. Pandya AA, Yakel JL. Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies. Biochem Pharmacol 2013 May 31.